It has been convincingly confirmed in vitro and in vivo in several animal models of human inflammatory and autoimmune diseases that controlled increase of ROS can be beneficial for the pathological conditions caused by insufficient NOX2 activity in neutrophils, e.g., CGD (74), RA (7, 24), and systemic lupus erythematosus (77). This evidence concerns the gene CYBB and chronic granulomatous disease.